Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
Erleada 60mg belongs toa group ofantiandrogens, and actionby an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it inhibits the effects of these hormones in the prostate gland and elsewhere in the body.
Erleada 60mg is a prescription medicine used under the guidance of medical practioners. It is unknown if Erleada is safe or persuasive in children
Erleada 60mg is used for the treatment in patients having nonmetastatic castration-resistant prostate cancer (NM-CRPC)
Apalutamide belongs to group of a small molecule and androgen receptor (AR) antagonist with probably antineoplastic activity. Apalutamide joints to AR in target tissues thereby inhibiting androgen-induced receptor activation and promote the formation of inactive complexes that cannot be translocated to the nucleus. This prohibits binding to and transcription of AR-responsive genes. This basically inhibits the expression of genes whichcontrol prostate cancer cell multiplication and may cause to aprevention of cell growth in AR-expressing tumor cells.
Absorption: duration to peak plasma concentration is 2hr and peak plasma concentration is 6mcg/mL and 5.9mcg/mL and steady-state achieved is 4 weeks
Distribution: human plasma protein binding of Apalutamide is 96% and N-desmethyl Apalutamide
Metabolism: primarily the drug metabolized by CYP2C8 for the formation of N-desmethyl Apalutamide
Elimination: Apalutamide excreted via urine 65% and feces 24%
Half-life is 3 days
For adult,Erleada usual dose is 240mg administrated four tablets involving 60mg given orally once daily.
The whole tablet should be swallow
Erleada tablet can be consume with or without food
Associated with Apalutamide the patients should also getting a gonadotropin-releasing hormone (GnRH) associated concurrently or should have had a bilateral orchiectomy
While patients have ≥ grade 3 toxicity or intolerable side effect then dosage modification should have required
Wait dosing until symptoms improve to ≤Grade 1 or original grade, after that proceed at the same dose or a decreased dose (180 mg or 120 mg), if warranted
Erleada has caused some side effect but most people will not affect all the side effect listed
Erleada interaction with strong CYP2C8 or CYP3A4 inhibitor is determined to have high the steady state exposure of the active molecule.
Erleada interaction with mainly metabolized by CYP3A4, CYP2C19 or CYP2C9 can reported in reduce exposure to these medications
Erleada is contraindicated in pregnant women because it will lead risk to fetal and probably loss of pregnancy
While using Erleada 60mg tablets will causes falls and fractures, patients should evaluate for risk and monitor and manage patients at risk for fractures along with established treatment guidelines.
Erleada 60mg may causes seizures then permanently discontinue if seizure occurs during treatment. Hence advise patients about developing risk due to seizure, it may lead to sudden loss of memory while engaging in activities.
The drug is not used for females and there is no data regarding using during pregnancy, based on its pharmacological action, Erleada will cause harm to fetal and probably loss of pregnancy
Erleada is not indicated for female patients
Store the drug at 200C to 250C
Store in the original container
Protect from light and moisture
If dose is missed, then take the dose as soon as possible before reach of next dose time or skip the missed dose and follow the normal schedule. Do not have extra dose which leads to over dosage
Consult the doctor about missed dose and overdose
Вижте офертите за акции. Хубаво е да се спаси!View all